Outcomes of using Firebird rapamycin eluting stents in routine coronary intervention practice: one-year results from the pilot study of Firebird in China registry

摘要

Recent clinical trials with rapamycin-eluting stents have shown very low restenosis rates. However, the higher penetration of drug eluting stent (DES) in China is being limited by the high costs of these imported devices, especially when considering multiple stenting. Firebird (Microport Co. Ltd., China) is a rapamycin (Huadong Pharmaceutical, China) polymer-based eluting stent with reasonable cost. The objective of this study was to evaluate the safety and efficacy of using Firebird stents in routine interventional practice.